Alzheimer’s Disease Treatment Global Market Research Report 2021 Featuring Allergan, Eisai, Novartis, Pfizer, Merz Pharma, H. Lundbeck A/S Biogen, AstraZeneca, and F. Hoffmann-La Roche

DUBLIN, December 08, 2021– (BUSINESS WIRE) – The report “Alzheimer’s Disease Treatment Global Market Report 2021: COVID-19 Growth and Change to 2030” has been added to ResearchAndMarkets.com offer.

The global Alzheimer’s disease treatment market is expected to grow from $ 3.43 billion in 2020 to $ 3.76 billion in 2021 at a compound annual growth rate (CAGR) of 9.6%. The market is expected to reach $ 5.91 billion in 2025 at a CAGR of 12%.

The major players in the Alzheimer’s disease treatment market are Allergan, Eisai Co. Ltd., Novartis AG, Pfizer Inc., Merz Pharma, H. Lundbeck A / S Biogen, AstraZeneca and F. Hoffmann-La Roche Ltd.

The global Alzheimer’s disease treatment market consists of the sale of drugs used to treat Alzheimer’s disease. Alzheimer’s disease is a progressive neurological disorder causing degeneration of brain cells, resulting in dementia (a disease that results in a decline in thinking, behavioral and social skills). The progression of this disease leads to severe memory impairment and the person may lose the ability to perform daily tasks.

The Alzheimer’s Disease Treatment market covered in this report is segmented by Drug Class Into Cholinergic, Memantine, Combination Drug, AChE Inhibitors, Immunoglobulins, and By Drug Type Into Cholinesterase Inhibitors, NMDA Receptor Antagonists .

Lack of techniques for diagnosing Alzheimer’s disease (AD) is expected to limit the growth of the global Alzheimer’s disease treatment market. There is no definitive blood test, brain scan, or physical exam to diagnose AD, and so many conditions can produce symptoms like dementia, which is the main clinical symptom of AD, which complicates the diagnosis.

In the absence of a single test for diagnosis, specialists such as neurologists, neuropsychologists, geriatricians and geriatric psychiatrists use a variety of diagnostic approaches to confirm dementia, but it is still difficult to find the cause leading to late diagnosis. Lack of proper and timely diagnosis for AD is hampering market growth as it leads to reduced number of diagnosed cases and thus reduces consumption of AD drugs.

The story continues

The increase in Alzheimer’s cases is a major factor contributing to the growth of the Alzheimer’s disease treatment market. Alzheimer’s disease is the most common type of dementia. The USA Alzheimer’s Association expects all states in the United States to face an increase of at least 14% in the number of people with Alzheimer’s disease between 2017 and 2025 due to the increase of the geriatric population. Globally, the estimated number of new Alzheimer’s cases is expected to increase by 35% to 615,000 by 2030, and by 110% to 959,000 by 2050. As a result, the increasing prevalence of Alzheimer’s disease is expected to stimulate the growth of Alzheimer’s disease worldwide. disease treatment market.

Increasing R&D investments and collaborations due to emerging treatment technologies is a key trend in the Alzheimer’s disease (AD) treatment market. The Alzheimer’s Association provides financial support for researchers seeking innovative therapeutic approaches and is seeking more public funding for studies on Alzheimer’s disease.

Main topics covered:

1. Summary

2. Characteristics of the Alzheimer’s disease treatment market

3. Alzheimer’s Disease Treatment Market Trends and Strategies

4. Impact of COVID-19 on the treatment of Alzheimer’s disease

5. Size and Growth of Alzheimer’s Disease Treatment Market

5.1. Historical Global Alzheimer’s Disease Treatment Market, 2015-2020, in USD Billion

5.1.1. Market pilots

5.1.2. Market restrictions

5.2. Global Alzheimer’s Disease Treatment Forecast Market, 2020-2025F, 2030F, in USD Billion

5.2.1. Market pilots

5.2.2. Market restrictions

6. Alzheimer’s disease treatment market segmentation

6.1. Global Alzheimer’s Disease Treatment Market Segmentation By Drug Class, History and Forecast, 2015-2020, 2020-2025F, 2030F, in USD Billion

• Cholinergic

• Memantine

• Combined drug

• AChE inhibitors

• Immunoglobulins

6.2. Global Alzheimer’s Disease Treatment Market Segmentation by Drug Type, History and Forecast, 2015-2020, 2020-2025F, 2030F, in USD Billion

6.3. Global Alzheimer’s Disease Treatment Market Segmentation By Therapeutics, History and Forecast, 2015-2020, 2020-2025F, 2030F, in USD Billion

7. Regional and Country Analysis of Alzheimer’s Disease Treatment Market

7.1. Global Alzheimer’s Disease Treatment Market Divided by Region, Historical and Forecast, 2015-2020, 2020-2025F, 2030F, in USD Billion

7.2. Global Alzheimer’s Disease Treatment Market Divided by Country, Historical and Forecast, 2015-2020, 2020-2025F, 2030F, in USD Billion

Companies mentioned

• Allergan

• Eisai Co. Ltd.

• Novartis AG

• Pfizer Inc.

• Merz Pharma

• H. Lundbeck A / S Biogen

• AstraZeneca

• F. Hoffmann-La Roche Ltée

• Eli Lilly and company

• Teva Pharmaceutical Industries Ltd.

• ONO Pharmaceutical Co. Ltd.

• Therapeutic VTV

• TauRx

• AC Immunized

• AB Sciences

• AbbVie Inc.

• Bristol-Myers Squibb Company

• Takeda Pharmaceutical Company Limited.

• Bayer AG

• Amgen

• UCB

• Forestry laboratories

• Merck Sharp & Dohme Corp.

• Biogenic

For more information on this report, visit https://www.researchandmarkets.com/r/m0fzzi

See the source version on businesswire.com: https://www.businesswire.com/news/home/20211208005828/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Director
press@researchandmarkets.com
For EST office hours, call 1-917-300-0470
For USA / CAN call toll free 1-800-526-8630
For GMT office hours, call + 353-1-416-8900